Optic neuritis in the era of biomarkers.

Aquaporin 4 / metabolism Biomarkers / metabolism Humans Myelin-Oligodendrocyte Glycoprotein / metabolism Optic Neuritis / diagnosis Prognosis
aquaporin-4 antibodies (AQP4-IgG) multiple sclerosis myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) neuromyelitis optica spectrum disorder (NMOSD) optic neuritis

Journal

Survey of ophthalmology
ISSN: 1879-3304
Titre abrégé: Surv Ophthalmol
Pays: United States
ID NLM: 0404551

Informations de publication

Date de publication:
Historique:
received: 05 06 2019
revised: 24 07 2019
accepted: 05 08 2019
pubmed: 20 8 2019
medline: 4 3 2021
entrez: 20 8 2019
Statut: ppublish

Résumé

The Optic Neuritis Treatment Trial, a landmark study completed in 1991, stratified the risk of multiple sclerosis in patients with optic neuritis. Since that time, unique biomarkers for optic neuritis have been found. The antibody against aquaporin-4 (AQP4)-immunoglobulin G (IgG) discovered in 2004 was found to be both the pathologic cause and a reliable biomarker for neuromyelitis optica spectrum disorders. This finding enabled an expanded definition of the phenotype of neuromyelitis optica spectrum disorder and improved treatment of the disease. Subsequently, myelin oligodendrocyte glycoprotein (MOG) IgG was recognized to be a marker for MOG-IgG-associated disorder, a central demyelinating disease characterized by recurrent optic neuritis, prominent disk edema, and perineural optic nerve enhancement on magnetic resonance imaging. Most multiple sclerosis disease-modifying agents are ineffective for AQP4-IgG-positive neuromyelitis optica spectrum disorder and MOG-IgG-associated disorder. Because there are crucial differences in treatment and prognosis between multiple sclerosis, AQP4-IgG-positive neuromyelitis optica spectrum disorder, and MOG-IgG-associated disorder, ophthalmologists should be aware of these new biomarkers of optic neuritis and incorporate their testing in all patients with atypical optic neuritis.

Identifiants

DOI: 10.1016/j.survophthal.2019.08.001 PMID: 31425702
pubmed: 31425702
pii: S0039-6257(19)30246-2
doi: 10.1016/j.survophthal.2019.08.001
pii:
doi:

Substances chimiques

Aquaporin 4 0
Biomarkers 0
Myelin-Oligodendrocyte Glycoprotein 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

12-17

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

John J Chen (JJ)

Department of Ophthalmology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Electronic address: Chen.john@mayo.edu.

Sean J Pittock (SJ)

Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

Eoin P Flanagan (EP)

Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

Vanda A Lennon (VA)

Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; Department of Immunology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

M Tariq Bhatti (MT)

Department of Ophthalmology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA; Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Canaux ioniques › Porines › Aquaporines › Aquaporine-4 › Optic neuritis in the era of biomarkers.
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Optic neuritis in the era of biomarkers.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Optic neuritis in the era of biomarkers.
questionsmedicales.fr › Facteurs biologiques › Antigènes › Autoantigènes › Glycoprotéine MOG › Optic neuritis in the era of biomarkers.
questionsmedicales.fr › Maladies de l'oeil › Atteintes du nerf optique › Névrite optique › Optic neuritis in the era of biomarkers.
questionsmedicales.fr › Diagnostic › Pronostic › Optic neuritis in the era of biomarkers.